All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Two-year follow-up of KTE-X19 in adult patients with R/R B-ALL: ZUMA-3 trial
The updated findings from the ZUMA-3 trial demonstrate that with longer follow-up and a larger pooled data set, outcomes remained stable over time in adult patients with R/R...
Blinatumomab overcomes the poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia
These findings support the use of blinatumomab in the treatment of pediatric patients...
"In partnership with the European School of Haematology, the ALL Hub will contribute to the dissemination of knowledge and favor fruitful translational discussions in the field of ALL."
Are you a healthcare professional? What is your speciality?
Please select or type your speciality
By sharing this information, you can help ensure we continue to develop content that is of most relevance for our audience.
Thank you for submitting.